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BACKGROUND: The degree of reperfusion is the most important modifiable predictor 
of 3-month functional outcome and mortality in ischemic stroke patients treated with 
mechanical thrombectomy. Whether the beneficial effect of reperfusion also leads to 
an improvement in long-term mortality is unknown. 
METHODS: Patients undergoing mechanical thrombectomy between 01/2010 and 
12/2018 were included. Post-thrombectomy degree of reperfusion and emboli in new 
territory were core-lab adjudicated. Reperfusion was evaluated according to the 
expanded thrombolysis in cerebral infarction scale (eTICI). Vital status was obtained 
from the Swiss population register. Adjusted hazard ratio (aHR) using time-split Cox 
regression models were calculated. Subgroup analyses were performed in patients 
with borderline indications. 
RESULTS: Our study included 1264 patients (median follow-up per patient: 2.5 years). 
Patients with successful reperfusion had longer survival times, attributable to lower 
hazards of death within 0–90 days and >90 days – 2 years (aHR 0.34, 95% CI 0.26–
0.46 and aHR 0.37, 95% CI 0.22–0.62). This association was homogeneous across 
all predefined subgroups (P for interaction >0.05). Among patients with successful 
reperfusion, a significant difference in hazards of death was observed between 
eTICI2b50 and eTICI3 (aHR 0.51, 95% CI 0.33–0.79). Emboli in new territory were 
present in 5% of patients, and were associated with increased mortality (aHR 2.3, 95% 
CI 1.11–4.86). 
CONCLUSION: Achievement of successful, and ideally complete, reperfusion without 





treated with mechanical thrombectomy, and this was evident across several 
subgroups.  
 
Non-standard Abbreviations and Acronyms 
ENHT  emboli in initially non-hypoperfused territory 
ENT  emboli in new territory 
LVO  large vessel occlusion 
MeVO  medium vessel occlusion 
MT  mechanical thrombectomy 
SAMS  Swiss Academy of Medical Sciences 







Randomized controlled trials have consistently shown that mechanical 
thrombectomy (MT) in acute ischemic stroke patients with large vessel occlusion in 
the anterior circulation reduces 3-month mortality.1 The REVASCAT and MR CLEAN 
follow-up studies demonstrated a sustained functional outcome benefit of added MT 
in the 1- and 2-year follow-up after the index stroke, respectively. However, there 
was no significant difference in mortality between the best medical treatment and MT 
groups, although the point estimates favored MT.2,3 Successful reperfusion is a 
potentially modifiable and important predictor of 3-month functional outcome after 
MT.4 However, long-term mortality after MT has only been investigated in a small 
real-world observational study (N=89).5 The aim of this study was to investigate the 
association of long-term mortality with reperfusion success applying the most recent 
modification of the expanded Thrombolysis in Cerebral Infarction (eTICI) scale6 in 
consecutive stroke patients treated with MT. 
Method 
Study Cohort 
This retrospective observational study included all consecutive patients treated with 
second-generation MT at a comprehensive stroke center between January 1, 2010 
and December 31, 2018 extracted from a single-center prospective stroke registry. 
Patients with missing long-term follow-up data or anterior-posterior and lateral post-
procedure angiographic imaging, as well as those with severe motion artifacts were 
excluded. The local ethics committee approved this study in accordance with Swiss 





consent for the assessment of long-term mortality was waived by the local ethics 
committee for patients who had not withdrawn their general consent.  
Endpoints 
The primary endpoint of this study was the survival rate during long-term follow-up 
and its association with post-thrombectomy reperfusion status. A TICI-score ≥ 2b50 
after MT was defined as successful reperfusion. The secondary endpoints were the 
relation between long-term mortality and emboli in new territory (ENT) or emboli in 
initially non-hypoperfused territory (ENHT).7,8  
Data Collection  
Baseline data and 90-day follow-up data from all consecutive patients who 
underwent MT between 01/2010 and 12/2018 were extracted from the local stroke 
registry. Their vital status was extracted between 09/2019 and 05/2020 from the 
Swiss Population Registry, which documents the vital status of all inhabitants of 
Switzerland every month. The follow-up time was defined as the interval between the 
index stroke treated with MT and the date of the last update of the Swiss Registry. 
For deceased patients, the follow-up time was defined as the interval between MT 
and the date of death. Reperfusion success was core-lab adjudicated by 3 
neuroradiologists (J.K., C.K., E.P.) using the most recent modification of the eTICI 
scale proposed by Liebeskind et al.6 In brief, eTICI2a, eTICI2b50, and eTICI2b67 
reflect capillary reperfusion in less than half (1–49%), 50–66%, and 67–89% of the 
target territory, respectively. Reperfusion of 90–99% is graded as eTICI2c, while 
eTICI3 indicates complete reperfusion.6 The reliability of the core lab was validated 
using a random sample of 142 patients and by calculating interrater reliability 





achieving eTICI2c/3 after one MT maneuver.9,10 ENT was defined as a new 
occlusion in a territory unaffected at baseline (i.e. in a territory not distal to the initial 
occlusion site) .11 An ENHT was defined as an emboli in a territory distal to the 
occlusion site, but without hypoperfusion on initial imaging (e.g. A2 emboli after a 
Carotid-T occlusion were the ACA territory was initially perfused via the AcomA, see 
eFigure I for illustration).7 
Statistical Analysis  
Baseline characteristics of included and excluded patients, as well as patients with 
successful versus unsuccessful reperfusion were compared using Fisher’s exact test 
and the Mann-Whitney U-test, depending on the variable type. The main outcome of 
the survival analysis was the survival rate with strata of successful versus 
unsuccessful reperfusion of different eTICI scores. Right-censored data over a time 
frame of 2556.75 days (=7 years) were considered for statistical analysis. We 
censored data at 7 years because the population at risk was below 10 patients per 
group in the main analysis. Kaplan-Meier curves were plotted to display survival 
rates with strata of angiographic reperfusion success, and Kaplan-Meier estimates 
were used to describe survival rates at 90 days, 2 years, and 5 years. Semi-
parametric multivariable Cox regression with a robust variance estimate was used to 
calculate aHRs and corresponding 95% confidence intervals (95% CI). All models 
included the following clinically selected covariates influencing outcome in stroke 
patients: age, sex, year of treatment, pre-stroke disability, arterial hypertension, 
dyslipidemia, history of smoking, coronary artery disease, previous stroke, National 
Institutes of Health Stroke Scale (NIHSS) on admission, occlusion site, time from 
symptom-onset/last-seen-well to groin puncture, and intravenous alteplase. Because 





interest (see Supplementary Methods 1 for further details), we used the following 
time splits to allow for varying hazard ratios over time: 0–90 days, >90 days – 2 
years (>90 – 730.5 days), and 2–7 years (>730.5–2556.75 days). The rationale for 
these time splits was that the survival rate dropped soon after the index event and 
stabilized thereafter. Additionally, visual inspection of landmark Kaplan-Meier curves 
showed evidence of different hazards of death between 90 days and 2 years for 
patients with successful and unsuccessful reperfusion, but not thereafter. Subgroup 
analyses regarding the association of successful versus unsuccessful reperfusion 
with survival rates were performed for the period 0–2 years. The following subgroups 
were used: ASPECTS (0–5, 6–8, and 9–10), MeVO (medium vessel occlusion) 
versus LVO (large vessel occlusion), and anterior versus posterior circulation 
occlusions. To evaluate the heterogeneity of aHRs across the subgroups, interaction 
terms of the abovementioned subgroups with successful versus unsuccessful 
reperfusion were incorporated into the multivariable Cox regression model for the 
period from day 0 – 2 years. The last step was a sensitivity analysis using between-
group symmetry metrics based on the restricted mean survival time at 1, 2, and 5 
years, respectively. These analyses were adjusted with an ANCOVA-type analysis. 
Analyses were performed using R (v 3.6.0, R Core Team). Further details of the R 
packages used can be found in the Supplementary Methods 2. Statistical 
significance level was defined as α = 0.05 and all tests were 2-sided.  
Results 
Study Population  
Altogether, 1313 patients who underwent MT between 01/2010 and 12/2018 were 





Population Registry, 9 with an unknown date of death) and 1276 had known vital 
status at the time of follow-up (eFigure II in the Data Supplement). A further 12 
patients were excluded because of missing anterior-posterior and lateral post-
procedure angiographic imaging or severe motion artifacts. After censoring of data 
with N<10 per stratum at risk (see Methods), median follow-up was 2.5 years, 
corresponding to a cumulative follow-up of 3498 patient–years. 
Baseline Characteristics 
There were some significant differences in baseline characteristics between included 
and excluded patients (eTable I in the Data Supplement). Patients who were 
included had lower ASPECTS scores (8 versus 7, P=0.03), higher NIHSS on 
admission, and distribution of occlusion sites was different. No differences in the rate 
of successful reperfusion were seen between included and excluded patients (86.9% 
versus 81.1%, P=0.32). 
Of the patients who were included, those with successful reperfusion (n=1098) 
represented 86.9% and those with unsuccessful reperfusion (n=166) represented 
13.1% of the study population.  
Baseline characteristics of included patients with successful and unsuccessful 
reperfusion are summarized in Table 1. Patients in whom reperfusion was successful 
had shorter intervals from onset time to groin puncture (median: 232 min, IQR: 168–
357 min, P<0.01) than patients in whom reperfusion was unsuccessful (median: 
249.5 min, IQR: 185–445). ASPECTS was higher in patients with successful 
reperfusion (median: 8 versus 7, IQR: 6–9 versus 5.5–8, P<0.01) and more patients 
in this group received intravenous alteplase (41.7% versus 30.1%, P<0.01).  





Observed 90-day, 2-year, and 5-year survival rates were 53.6% versus 78.0%, 
41.8% versus 69.0%, and 38.1% versus 59.8% for patients with unsuccessful and 
successful reperfusion, respectively (Figure 1A, log-rank test P<0.01). On 
multivariable Cox regression, after adjusting for prespecified covariates (see 
Methods), successful reperfusion was associated with lower hazards of death within 
the period from 0–90 days (aHR 0.34, 95% CI 0.26–0.45, Figure 2A and Figure 3) 
and >90 days–2 years (aHR 0.37, 95% CI 0.22–0.62, Figure 2B and Figure 3). 
During the period from 2–7 years there was no significant difference regarding the 
hazards of death between the groups (aHR 1.13, 95% CI 0.39–3.28, Figure 2B and 
Figure 3).  
The reduced hazards of death between day 0 and 2 years in patients who had 
undergone successful reperfusion were noted in all prespecified subgroups and 
there was no evidence of significant heterogeneity (eFigure III). Specifically, the 
aHRs of achieving successful reperfusion were 0.49 (95% CI 0.27–0.88) for MeVO, 
0.33 (95% CI 0.08–1.30) for posterior circulation strokes, and 0.36 (95% CI 0.22–
0.58) for patients with ASPECTS 0–5. Moreover, the associations of reperfusion 
success and mortality was discernible in patients treated between 2010 and 2014 
and those treated between 2015 and 2018 (eFigure IV).  
Association between Grade of Successful Reperfusion and Long-term 
Mortality 
The observed 90-day, 2-year, and 5-year survival rates of patients with different 
grades of successful reperfusion are shown in Supplementary Table 2. Significantly 
longer survival was observed in patients with eTICI3 as opposed to eTICI2b50 and 





the reperfusion grade, the lower the hazard ratios on multivariable Cox regression 
(eFigure V in the Data Supplement). Achieving eTICI3 was associated with a 
reduced hazard of death when compared to eTICI2b50 (eTICI2b50 as reference, 
aHR 0.46, 95% CI 0.30–0.74). This difference was evident in the first 90 days after 
the index event, but no differences in the hazards of death between different grades 
of successful reperfusion were seen thereafter (eFigure V in the Data Supplement). 
Overall, a first-pass eTICI2c/3 was associated with reduced long-term mortality 
(eFigure VI). 
Association between ENT and/or ENHT and Long-term Mortality 
There were 52 ENT (in 3 cases ENT in multiples branches) and 12 ENHT, leading to 
new embolisations in 63 patients (one patient with both ENT and ENHT) out of 1264 
patients (5.0%). 23% (n=23) were defined as proximal ENT/ENHT, with embolisation 
present in the M3-Segment of the Artery Cerebri Media, A2-Segment of the Artery 
Cerebri Anterior and P2-Segment of the Artery Cerebri Posterior or more proximally. 
Observed 90-day, 2-year, and 5-year survival rates were 75.2% versus 66.7%, 
66.2% versus 52.2%, and 58.0% versus 40.9% for patients with and without 
ENT/ENHT, respectively (log-rank test P<0.01, eFigure VII in the Data Supplement). 
Occurrence of ENT/ENHT differed across eTICI scores, with more ENT/ENHT 
observed after higher TICI grades (eTable III in the Data Supplement). After 
adjusting for confounders (see methods) and eTICI, occurrence of ENT/ENHT was 
independently associated with increased hazards of death in the 91–730 day period 
(aHR 2.15, 95% CI 1.04–4.44, eFigure VIII in the Data Supplement). Mortality was 






Sensitivity Analyses using Restricted Mean Survival Time Estimates 
Crude and adjusted differences in restricted mean survival times according to 
reperfusion quality corroborated most of the results noted above (see eTable IV in 
the Data Supplement for an overview). In the adjusted analyses, patients with 
successful reperfusion had higher mean survival across all potential follow-up 
intervals (e.g., net restricted mean survival difference at 5 years: 329 days [95% CI 
204–455 days]). Restricted mean survival differences for TICI3 versus TICI2b50 
were only significant when considering follow-up times of 1 year and 2 years (e.g., 
net mean survival difference at 2 years: 64 days [95% CI 7–121 days]). The 
association of ENT/ENHT with long-term mortality was only significant in the 
unadjusted analyses (eTable IV in the Supplement).  
 
Discussion 
The main findings of this study are: (1) Successful reperfusion defined as eTICI ≥ 
2b50 is associated with lower mortality during long-term follow-up, which is 
attributable to lower hazards of death in the first 2 years. (2) This association was 
also evident in borderline indication groups, including patients presenting with low 
ASPECTS, posterior circulation strokes, or medium vessel occlusions. (3) Among 
patients with successful reperfusion, increasing reperfusion grade was associated 
with lower mortality and significant differences were observed between eTICI2b50 
and eTICI3. (4) The occurrence of ENT/ENHT may lead to an additional increase in 
the risk of long-term mortality. 





In the Third International Stroke Trial (IST-3), intravenous thrombolysis was not 
associated with any overall survival benefit after 3 years.12 However, there was a 
significantly lower hazard of death between 8 days and 3 years if patients survived 
the early period during which an increased risk of death following intravenous 
thrombolysis was observed.12 MT has been shown to further improve reperfusion 
rates. This has been suggested to be one of the main drivers of therapy success in 
the pivotal MT trials comparing best medical treatment (BMT) with MT.13 
Correspondingly, MT was associated with a reduction in 3-month mortality as 
compared to BMT alone.1 The 1- and 2-year follow-up of the MR CLEAN and 
REVASCAT trial did not find a significant reduction of mortality in patients receiving 
MT2,3; however, these trials were not powered to detect such an effect. Moreover, a 
meta-analysis of these 2 studies and the 1-year follow-up of the IMS III trial14 yielded 
point estimates favoring MT (OR 0.82; 95% CI 0.63–1.06; P=0.12).15 In our study of 
consecutive patients undergoing MT, which had a cumulative follow-up of 3498 
years, successful reperfusion was associated with a sustained survival benefit. 
Importantly, this was also observed in a subset of patients with borderline indications 
with no evidence of relevant heterogeneity. Although these observations may not be 
a sufficient basis for treatment recommendations even if all-cause mortality is 
considered as a relevant outcome, they may serve as an indicator of potential 
therapy effect. This is also supported by data suggesting that outcome for patients 
with unsuccessful reperfusion is not worse than that of patients treated with BMT.16 
Certainly, avoiding mortality is only one aspect of a potential treatment benefit and 
the definition and interaction between good functional outcome, patient-reported 
quality of life17, and what constitutes futile reperfusion are still under discussion.18 





objective “hard” endpoint. Interestingly, the association of reduced hazards of death 
was relatively stable throughout the first 2 years, suggesting that the observed 
difference cannot solely be attributed to higher survival rate in successfully 
reperfused patients in the hyperacute and acute phase. Reassuringly, the observed 
survival differences, which were accumulated over the first 2 years, were not 
attenuated in the very long-term follow-up as evidenced by comparable hazards of 
death in survivors at 2 years following successful and unsuccessful reperfusion. 
Beyond Successful Reperfusion and Emboli in New Territory 
More complete reperfusion beyond TICI2b was associated with reduced disability 
and lower day-90 mortality. However, the magnitude of this association differed 
considerably across cohorts and grading systems.19–21 Liebeskind et al. recently 
proposed the 7-point eTICI score, which adds prognostic value due to being finer 
grained in the > 50% reperfusion categories.6 Substantial differences in clinical 
outcomes were observed when applying the newly proposed subdivisions of 50–66% 
(eTICI2b50), 67–89% (eTICI2b67), and 90–99% (eTICI2c) in the 90-day follow-up of 
the HERMES data.6 Liebeskind et al. found that day-90 mortality in patients with 
TICI2b50 reperfusion (12.6%) was double that of patients with eTICI3 reperfusion 
(6.3%), whereas mortality rates of patients with TICI2b67 and TICI2c were in 
between.6 Moreover, we found an association between ENT/ENHT and increased 
mortality. Although angiographically-graded ENT/ENHT underestimates the true rate 
of emboli,7,22 previous studies have shown that angiographically evident ENT/ENHT 
are associated with increased disability.7,22,23 It therefore seems likely that efforts 
aimed at further decreasing thrombus fragmentation would also reduce long-term 
mortality. Moreover, there is an ongoing debate on whether patients with successful 





This is especially relevant as distal thrombectomy has been reported to be safe and 
technically feasible, as well as potentially beneficial, and dedicated devices have 
been introduced to the market.25,26 Moreover, post-thrombectomy intra-arterial 
thrombolysis is still favored by some interventionalists.27,28 Lastly, the observed 
beneficial effects of first-pass TICI2c/3 fit well into recent observations of a beneficial 
effect of first-pass complete reperfusion.9,10,29 
Limitations 
This retrospective and observational study has several limitations. First, 49 patients 
(3.7%) were lost to follow-up, which may have resulted in bias as patients with 
available follow-up data had different baseline characteristics to those without. 
Second, as all patients were treated at one center, the findings may not be 
generalizable. Third, although patients were treated with a second-generation 
devices, MT was not a well-established as acute stroke therapy at the beginning of 
the recruitment period, which could introduce bias regarding interventionalist 
experience and in-hospital work-flows. Fourth, a control group of patients without MT 
is lacking and a comparison of successful versus unsuccessful reperfusion as the 
means of estimating potential treatment effects is biased, because non-captured 
variables could have influenced the operators’ decision to stop the intervention or 
use further bailout strategies. Hence, the surmised association between successful 
reperfusion and reduced mortality may be too favorable. Fifth, other potential 
confounders, such as secondary prophylaxis, medication adherence, and general 
care, which may influence mortality after the index stroke, could not be included in 
the multivariate analysis. Last, landmark analyses were carried out to allow for 
changing hazard ratios of the variables of interest as well as covariates over time, 






Achieving successful, and ideally complete reperfusion, is associated with long-term 
mortality reduction in patients undergoing MT for an acute ischemic stroke, even if 
they have borderline indication criteria. This study also suggests a potential 
association between ENT/ENHT and increased mortality. Technical advances 
geared toward improving angiographic reperfusion and reducing peri-interventional 
embolisation in new territory may improve long-term survival. 
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Figure 1 – Kaplan-Meier curves with strata of reperfusion success  
A, Survival curve with 95% confidence intervals according to strata of successful reperfusion 
(defined as eTICI2b50–eTICI3). Patients with successful reperfusion had higher survival rates 
(log-rank test P<0.01). At 5 years, estimated survival of patients with successful reperfusion 
was 59.8%, whereas in those with unsuccessful reperfusion it was 38.1%. B, Kaplan-Meier 
curve confined to patients with successful reperfusion. Significant differences in survival were 
observed when comparing eTICI3 with eTICI2b50 (log-rank test P=0.02), as well as comparing 
eTICI2c/3 with eTICI2b50+TICI2b67 (log-rank P=0.04).  
eTICI indicates expanded Thrombolysis in Cerebral Infarction.  
 
Figure 2 – Landmark Kaplan-Meier curves with strata of successful reperfusion 
A, Kaplan-Meier curve with landmark analysis set at 90 days and truncated at 730 days 
displaying the first 2 periods selected for the split analysis. Lower hazards of death in patients 
with successful reperfusion are seen during both time periods, corresponding to the adjusted 
hazard ratio of 0.34 and 0.37 observed for these periods on multivariable Cox regression 
analyses; B, In patients who survived the first 2 years, hazards of death did not differ between 
patients with successful and unsuccessful reperfusion, suggesting that the cumulative survival 
difference seen in the first 2 years appears to be sustained on long-term follow-up up to 7 
years.  






Figure 3 – Crude and adjusted hazard ratios of successful reperfusion in different follow-up 
periods 
Crude and adjusted hazard ratios were calculated by applying Cox regression models either 
with successful versus unsuccessful reperfusion only, or with additional adjustments for 
covariates as outlined in the Methods section. Cox regression models were run separately for 
each prespecified landmark period. There were comparable hazard ratios of achieving 
successful reperfusion within the first 90 days and from >90 days – 2 years suggesting 
continuing lower hazards of death within the first 2 years if reperfusion is successful. After 2 
years, the cumulated survival difference remained stable, without significant differences in the 
hazards of death between patients with successful and unsuccessful reperfusion who had 
survived the first 2 years (period 2–7 years).  
eTICI indicates expanded Thrombolysis in Cerebral Infarction; 95% CI, 95% confidence 













(eTICI 0– eTICI2a, 
N=166) 
P value 
Baseline     
Age at admission 
(median, IQR, y) 
74.25 (60.06–82.16) 
 
74.41 (62.1–82.2) 73.76 (62–82.03) 0.98 
Sex, female, No./total 
No. (%) 
630/1264 (49.8) 544/1098 (49.5) 86/166 (51.8) 0.62 
Independence before 
stroke 
No./total No. (%) 
1111/1258 (88.3) 971/1094 (88.8) 140/164 (85.4) 0.24 
Risk factors No./total No. (%)    
Diabetes 215/1260 (17.1) 185/1094 (16.9) 30/166 (17.5) 0.74 
Hypertension 883/1261 (70) 771/1095 (70.4) 112/166 (67.5) 0.47 
Dyslipidemia 697/1254 (55.6) 611/1090 (56.1) 86/164 (52.4) 0.40 
Smoking 304/1255 (24.2) 266/1092 (24.4) 38/163 (23.3) 0.84 
Previous stroke 156/1262 (12.4) 141/1096 (12.9) 15/166 (9.6) 0.20 
Coronary artery disease 243/1254 (19.4) 212/1090 (19.4) 31/164 (18.9) 0.92 
Stroke characteristics    
Time to admission 
(median, IQR) 
150 (79–272) 149 (77.5–261.5) 165 (88.5–320) 0.1 
Transfer patients 
No./total No. (%) 
430/1263 (34) 373/1097 (34) 57/166 (34.3) 0.93 
Admission MRI  
No. / total No. (%) 
644/1621 (51.1) 555/1096 (50.6) 76/165 (53.9) 0.45 
Time to groin puncture 
(median, IQR) 
237 (170–364) 232 (168–357) 249.5 (185–445) 0.004* 
ASPECTS 
(median, IQR) 
8 (6–9) 8 (6–9) 7 (5.5–8) 0.002* 
NIHSS on admission  
(median, IQR) 
15 (9–20) 15 (9–20) 15 (9–20) 0.44 
Dichotomized NIHSS (≥ 
5) 
No./total No. (%) 






Table 1. Comparison of Baseline Characteristics Between Patients with Successful 
and Unsuccessful Reperfusion 
Anterior circulation  
No./total No. (%) 
1159/1264 (91.7) 1002/1098 (91.3) 157/166 (94.6) 0.17 
Site of occlusion No./total No. (%) 
Internal carotid artery 310/1263 (24.5) 271/1907 (24.7) 39/166 (23.5) 
0.001* 
M1 638/1263 (50.5) 567/1097 (51.7) 71/166 (42.8) 
M2 198/1263 (15.7) 154/1097(14) 44/177 (26.5) 
Posterior circulation 104/1263 (8.2) 95/1097(8.7) 9/166 (5.4) 
Other occlusion  13/1263 (1) 10/1097(0.9) 3/166 (1.8) 
TOAST No./total No. (%) 
Large‐artery 
atherosclerosis  
146/1260 (11.6) 124/1094 (11.3) 22/166 (15.1) 
0.04* 
Cardioembolism 541/1260 (42.9) 486/1094 (44.4) 55/166 (33.1) 
Stroke of other 
determined etiology 
84/1260 (6.7) 69/1094 (6.3) 15/166 (9.0) 
Stroke of undetermined 
etiology 
489/1260 (38.8) 415/1094 (37.9) 74/166 (44.6) 
Stroke treatment 
IVT No./total No. (%) 508/1264 (40.2) 458/1098 (41.7) 50/166 (30.1) 0.005* 
ENT/ENHT No./total No. 
(%) 
63/1264 (5) 58/1098 (5.3) 5/166 (3) 0.25 
eTICI indicates expanded Thrombolysis in Cerebral Infarction; IQR, interquartile range; ASPECTS, Alberta Stroke Program Early 
CT Score; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; ICA, internal 
carotid artery; M1, first segment of the middle cerebral artery; M2, second segment of the middle cerebral artery; IVT, intravenous 
thrombolysis; ENT, embolus in new territory; ENHT, embolus in initially non-hypoperfused territory; *, P<0.01. 
